Global DNA and RNA Methylation Signature in Response to Antipsychotic Treatment in First-Episode Schizophrenia Patients.
5hmC
5mC
global methylation
m6A
schizophrenia
treatment response
Journal
Neuropsychiatric disease and treatment
ISSN: 1176-6328
Titre abrégé: Neuropsychiatr Dis Treat
Pays: New Zealand
ID NLM: 101240304
Informations de publication
Date de publication:
2024
2024
Historique:
received:
29
02
2024
accepted:
18
06
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
25
7
2024
Statut:
epublish
Résumé
Schizophrenia is a heterogeneous chronic psychiatric disorder influenced by genetic and environmental factors. Environmental factors can alter epigenetic marks, which regulate gene expression and cause an array of systemic changes. Several studies have demonstrated the association of epigenetic modulations in schizophrenia, which can influence clinical course, symptoms, and even treatment. Based on this, we have examined the global DNA methylation patterns, namely the 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC); and the global RNA modification N6-methyladenosine (m6A) RNA methylation status in peripheral blood cells. First-Episode Psychosis (FEP) patients who were diagnosed with Schizophrenia (SCZ) and undergoing treatment were stratified as Treatment-Responsive (TR) and Treatment-Non-Responsive (TNR). Age- and sex-matched healthy subjects served as controls. The methylation pattern of 5mC and 5hmC showed significant increases in patients in comparison to controls. Further, when patients were classified based on their response to treatment, there was a statistically significant increase in methylation patterns in the treatment non-responder group. 5fC and m6A levels did not show any statistical significance across the groups. Further, gender-based stratification did not yield any significant difference for the markers. The study highlights the increased global methylation pattern in SCZ patients and a significant difference between the TR versus TNR groups. Global 5mC and 5hmC epigenetic marks suggest their potential roles in schizophrenia pathology, and also in the treatment response to antipsychotics. Since not many studies were available on the treatment response, further validation and the use of more sensitive techniques to study methylation status could unravel the potential of these epigenetic modifications as biomarkers for SCZ as well as distinguishing the antipsychotic treatment response in patients.
Sections du résumé
Background
UNASSIGNED
Schizophrenia is a heterogeneous chronic psychiatric disorder influenced by genetic and environmental factors. Environmental factors can alter epigenetic marks, which regulate gene expression and cause an array of systemic changes. Several studies have demonstrated the association of epigenetic modulations in schizophrenia, which can influence clinical course, symptoms, and even treatment. Based on this, we have examined the global DNA methylation patterns, namely the 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC); and the global RNA modification N6-methyladenosine (m6A) RNA methylation status in peripheral blood cells. First-Episode Psychosis (FEP) patients who were diagnosed with Schizophrenia (SCZ) and undergoing treatment were stratified as Treatment-Responsive (TR) and Treatment-Non-Responsive (TNR). Age- and sex-matched healthy subjects served as controls.
Results
UNASSIGNED
The methylation pattern of 5mC and 5hmC showed significant increases in patients in comparison to controls. Further, when patients were classified based on their response to treatment, there was a statistically significant increase in methylation patterns in the treatment non-responder group. 5fC and m6A levels did not show any statistical significance across the groups. Further, gender-based stratification did not yield any significant difference for the markers.
Conclusion
UNASSIGNED
The study highlights the increased global methylation pattern in SCZ patients and a significant difference between the TR versus TNR groups. Global 5mC and 5hmC epigenetic marks suggest their potential roles in schizophrenia pathology, and also in the treatment response to antipsychotics. Since not many studies were available on the treatment response, further validation and the use of more sensitive techniques to study methylation status could unravel the potential of these epigenetic modifications as biomarkers for SCZ as well as distinguishing the antipsychotic treatment response in patients.
Identifiants
pubmed: 39049939
doi: 10.2147/NDT.S466502
pii: 466502
pmc: PMC11268744
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1435-1444Informations de copyright
© 2024 Angelin et al.
Déclaration de conflit d'intérêts
Ravi Sudesh was a DHR Young Scientist at Dr ALM PG Institute of Basic Medical Sciences, University of Madras, at the time the study was conducted. The authors declare that they have no competing interests in this work.
Références
Mol Biotechnol. 2020 Oct;62(10):467-484
pubmed: 32840728
Epigenomics. 2020 Jun;12(12):1041-1051
pubmed: 32657132
J Psychiatr Res. 2021 May;137:283-289
pubmed: 33730603
Trends Biochem Sci. 2013 Oct;38(10):480-4
pubmed: 23932479
Front Neurosci. 2021 May 13;15:674273
pubmed: 34054421
Mol Psychiatry. 2020 Aug;25(8):1718-1748
pubmed: 31907379
Cell Biosci. 2023 Nov 21;13(1):213
pubmed: 37990254
Neuromolecular Med. 2013 Mar;15(1):95-101
pubmed: 22961555
Acta Psychiatr Scand. 2006 Feb;113(2):91-5
pubmed: 16423159
Prog Neuropsychopharmacol Biol Psychiatry. 2020 Apr 20;99:109855
pubmed: 31911076
Cold Spring Harb Protoc. 2010 Jun;2010(6):pdb.prot5439
pubmed: 20516177
Front Neurosci. 2020 Feb 28;14:98
pubmed: 32184705
J Psychiatr Res. 2019 Jul;114:41-47
pubmed: 31022588
Nat Genet. 2021 Aug;53(8):1156-1165
pubmed: 34211177
J Psychiatr Res. 2007 Dec;41(12):1042-6
pubmed: 17049557
Neuropsychopharmacology. 2013 Jan;38(1):138-66
pubmed: 22948975
Signal Transduct Target Ther. 2021 Feb 21;6(1):74
pubmed: 33611339
Front Genet. 2018 Jul 12;9:243
pubmed: 30050561
Clin Pharmacol Ther. 2012 Dec;92(6):727-36
pubmed: 23093317
J Neural Transm (Vienna). 2023 Feb;130(2):165-169
pubmed: 36648581
Pharmacotherapy. 2020 Apr;40(4):331-342
pubmed: 32058614
Front Psychol. 2016 Sep 30;7:1496
pubmed: 27746755
Schizophr Res. 2008 Apr;101(1-3):50-7
pubmed: 18276118
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Neuron. 2018 Jul 25;99(2):389-403.e9
pubmed: 30048615
Biotechnol Biotechnol Equip. 2014 May 4;28(3):518-524
pubmed: 26019538
Epigenomics. 2018 Mar;10(3):233-247
pubmed: 29343074
Epigenomics. 2021 Jun;13(12):927-937
pubmed: 33942662
Epigenomics. 2023 Jan;15(1):21-38
pubmed: 36919681
EC Psychol Psychiatr. 2023;12(11):
pubmed: 38145106
Front Genet. 2017 Jul 19;8:100
pubmed: 28769976
Psychiatry Res. 2017 Nov;257:497-500
pubmed: 28841512
J Hum Genet. 2013 Feb;58(2):91-7
pubmed: 23235336
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Feb 2;81:38-49
pubmed: 29017764
J Affect Disord. 2019 Apr 15;249:336-346
pubmed: 30802699